IL158359A0 - Liquid pharmaceutical composition - Google Patents

Liquid pharmaceutical composition

Info

Publication number
IL158359A0
IL158359A0 IL15835902A IL15835902A IL158359A0 IL 158359 A0 IL158359 A0 IL 158359A0 IL 15835902 A IL15835902 A IL 15835902A IL 15835902 A IL15835902 A IL 15835902A IL 158359 A0 IL158359 A0 IL 158359A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
IL15835902A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158359(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL158359A0 publication Critical patent/IL158359A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IL15835902A 2001-05-25 2002-04-29 Liquid pharmaceutical composition IL158359A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
IL158359A0 true IL158359A0 (en) 2004-05-12

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15835902A IL158359A0 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Country Status (43)

Country Link
US (2) US20020198261A1 (de)
EP (1) EP1395242B1 (de)
JP (1) JP2004534764A (de)
KR (1) KR100582963B1 (de)
CN (1) CN100346779C (de)
AP (1) AP1815A (de)
AR (1) AR033922A1 (de)
AT (1) ATE334656T1 (de)
AU (1) AU2002258026B2 (de)
BG (1) BG108376A (de)
BR (1) BR0209973A (de)
CA (1) CA2446574C (de)
CR (1) CR7150A (de)
CY (1) CY1105147T1 (de)
CZ (1) CZ299755B6 (de)
DE (1) DE60213592T2 (de)
DK (1) DK1395242T3 (de)
DO (1) DOP2002000403A (de)
EA (1) EA008087B1 (de)
EE (1) EE200300587A (de)
EG (1) EG24078A (de)
ES (1) ES2265040T3 (de)
GE (1) GEP20053620B (de)
HR (1) HRP20030833B1 (de)
HU (1) HUP0401366A2 (de)
IL (1) IL158359A0 (de)
IS (1) IS2428B (de)
MA (1) MA27026A1 (de)
MX (1) MXPA03009392A (de)
MY (1) MY128615A (de)
NO (1) NO20035200D0 (de)
NZ (1) NZ529173A (de)
OA (1) OA12604A (de)
PA (1) PA8545901A1 (de)
PE (1) PE20030087A1 (de)
PL (1) PL366384A1 (de)
PT (1) PT1395242E (de)
RS (1) RS87203A (de)
SI (1) SI1395242T1 (de)
SK (1) SK286227B6 (de)
SV (1) SV2003001053A (de)
WO (1) WO2002094220A1 (de)
ZA (1) ZA200308393B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA05001643A (es) * 2002-08-15 2005-04-25 Pfizer Uso terapeutico de aminoacidos biciclicos y triciclicos condensados.
RU2353358C2 (ru) * 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
MXPA05006656A (es) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc Metodos de tratamiento de desordenes de vejiga no dolorosos usando moduladores del canal de calcio subunidad (2o.
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
MXPA06003725A (es) * 2003-10-08 2006-06-23 Mallinckrodt Inc Solucion de fenidato de metilo y metodos asociados de administracion y produccion.
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
US20080112893A1 (en) * 2004-10-14 2008-05-15 Arai Jun-Ichiro Atmosphere Modifying Method and Spray Agent and Spray Device Used in the Same
JP2009504613A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
EP1919861A2 (de) * 2005-08-11 2008-05-14 Boehringer Ingelheim International GmbH Verbindungen zur behandlung der alzheimer erkrankung
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2246044A1 (de) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Kinderärztliche Lösungen für Betablocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CA3131336A1 (en) * 2019-03-26 2020-10-01 Mirja Huhtinen Pregabalin formulations and use thereof
MX2023008647A (es) 2021-01-22 2023-08-01 Egyt Gyogyszervegyeszeti Gyar Formulacion topica que contiene pregabalina dispersada.
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
WO2022168968A1 (ja) * 2021-02-05 2022-08-11 学校法人近畿大学 末梢神経障害の予防又は改善剤
CN118139617A (zh) * 2021-08-31 2024-06-04 艾维恩制药有限公司 稳定的加巴喷丁粉体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
PL204921B1 (pl) * 1998-05-15 2010-02-26 Warner Lambert Co Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania
AP2001002360A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors.

Also Published As

Publication number Publication date
US20020198261A1 (en) 2002-12-26
KR20040003006A (ko) 2004-01-07
EP1395242B1 (de) 2006-08-02
SV2003001053A (es) 2003-03-18
GEP20053620B (en) 2005-09-26
OA12604A (en) 2006-06-08
CR7150A (es) 2004-02-23
CZ20033066A3 (cs) 2004-08-18
DK1395242T3 (da) 2006-10-30
IS6986A (is) 2003-10-09
HK1062646A1 (zh) 2004-11-19
ZA200308393B (en) 2005-04-26
SK286227B6 (sk) 2008-05-06
CA2446574A1 (en) 2002-11-28
DE60213592D1 (de) 2006-09-14
US7256216B2 (en) 2007-08-14
EA008087B1 (ru) 2007-02-27
HRP20030833B1 (en) 2007-04-30
ATE334656T1 (de) 2006-08-15
CN100346779C (zh) 2007-11-07
WO2002094220A1 (en) 2002-11-28
PL366384A1 (en) 2005-01-24
AP1815A (en) 2008-01-04
DOP2002000403A (es) 2002-11-30
EA200301152A1 (ru) 2004-04-29
NO20035200L (no) 2003-11-24
US20040072904A1 (en) 2004-04-15
EE200300587A (et) 2004-02-16
SK14112003A3 (sk) 2004-08-03
BG108376A (bg) 2005-04-30
CA2446574C (en) 2008-04-01
RS87203A (sr) 2006-10-27
AU2002258026B2 (en) 2007-08-02
AR033922A1 (es) 2004-01-07
JP2004534764A (ja) 2004-11-18
BR0209973A (pt) 2004-04-06
EG24078A (en) 2008-05-11
SI1395242T1 (en) 2006-10-31
EP1395242A1 (de) 2004-03-10
CZ299755B6 (cs) 2008-11-12
NO20035200D0 (no) 2003-11-24
AP2003002907A0 (en) 2003-12-31
ES2265040T3 (es) 2007-02-01
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
HRP20030833A2 (en) 2004-08-31
HUP0401366A2 (hu) 2004-11-29
KR100582963B1 (ko) 2006-05-24
MA27026A1 (fr) 2004-12-20
IS2428B (is) 2008-10-15
MY128615A (en) 2007-02-28
PE20030087A1 (es) 2003-02-14
PA8545901A1 (es) 2003-09-05
CN1509165A (zh) 2004-06-30
CY1105147T1 (el) 2010-03-03
DE60213592T2 (de) 2007-08-09
NZ529173A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
EG24078A (en) Liquid pharmaceutical composition
EP1450824A4 (de) Pharmazeutische zusammensetzung
HUP0302876A3 (en) Pharmaceutical formulation
GB0111597D0 (en) Pharmaceutical compositions
GB0118689D0 (en) Pharmaceutical formulation
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
PL366432A1 (en) Pharmaceutical formulation
EP1398040A4 (de) Medizinische zusammensetzung
GB0129117D0 (en) Pharmaceutical composition
EP1408896A4 (de) Pharmazeutische zusammensetzung
GB0116107D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
GB0114746D0 (en) Medicinal composition
GB2382302B (en) Pharmaceutical compositions
IL157411A0 (en) Pharmaceutical composition
GB0104749D0 (en) Pharmaceutical formulation
GB0125061D0 (en) Pharmaceutical composition
HU0103049D0 (en) Pharmaceutical composition
GB0126732D0 (en) Pharmaceutical compositions
GB0101584D0 (en) Pharmaceutical composition
GB0130957D0 (en) Pharmaceutical composition
GB0113074D0 (en) Pharmaceutical composition